Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations

Cancer Letters

Volumn 322, Issue 2, 2012, Pages 213-222

  Zhang, Xiang Hua ^a   Shin, Jung Young ^a   Kim, Jeong Oh ^a   Oh, Ji Eun ^a   Yoon, Seong Ae ^a   Jung, Chan Kwon ^b   Kang, Jin Hyoung ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

NSCLC; Paclitaxel; Sequential combination; Sorafenib; Xenograft mice

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; GENE FUNCTION; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; RAS PROTEINS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84861684344     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.015     Document Type: Article

References (49)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer Stat. 2010.
2. Jemal A., Siegel R., Xu J., Ward E. CA Cancer J. Clin. 2010, 60:77-300.
3. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S., van Bodegom P.C., Bos J.L. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988, 48:5738-5741.
4. Zhang X., Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int. J. Med. Sci. 2008, 5:209-217.
5. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., Weber B.L. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002, 62:6997-7000.
6. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
7. Ladanyi M., Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod. Pathol. 2008, 21(Suppl. 2):S16-22.
8. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., Bekele B.N., Herbst R.S., Wistuba KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 2007, 13:2890-2896.
9. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
10. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 2000, 351(Pt 2):289-305.
11. van Krieken J.H., Jung A., Kirchner T., Carneiro F., Seruca R., Bosman F.T., Quirke P., Flejou J.F., Plato Hansen T., de Hertogh G., Jares P., Langner C., Hoefler G., Ligtenberg M., Tiniakos D., Tejpar S., Bevilacqua G., Ensari A. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008, 453:417-431.
12. Wilhelm S., Chien D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 2002, 8:2255-2257.
13. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
14. Takezawa K., Okamoto I., Yonesaka K., Hatashita E., Yamada Y., Fukuoka M., Nakagawa K. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 2009, 69:6515-6521.
15. Yu C., Bruzek L.M., Meng X.W., Gores G.J., Carter C.A., Kaufmann S.H., Adjei A.A. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869.
16. Carter C.A., Chen C., Brink C., Vincent P., Maxuitenko Y.Y., Gilbert K.S., Waud W.R., Zhang X. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother. Pharmacol. 2007, 59:183-195.
17. Okamoto I., Miyazaki M., Morinaga R., Kaneda H., Ueda S., Hasegawa Y., Satoh T., Kawada A., Fukuoka M., Fukino K., Tanigawa T., Nakagawa K. Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest. New Drugs 2010, 28:844-853.
18. Rini B.I. Sorafenib. Expert Opin. Pharmacother. 2006, 7:453-461.
19. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., Abrao Miziara J.E., Balint B., De Marinis F., Keller A., Aren O., Csollak M., Albert I., Barrios C.H., Grossi F., Krzakowski M., Cupit L., Cihon F., Dimatteo S., Hanna N. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1835-1842.
20. Takimoto C.H., Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother. Pharmacol. 2008, 61:535-548.
21. Chang A.Y., Kim K., Glick J., Anderson T., Karp D., Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group Results. J. Natl. Cancer Inst. 1993, 85:388-394.
22. Murphy W.K., Fossella F.V., Winn R.J., Shin D.M., Hynes H.E., Gross H.M., Davilla E., Leimert J., Dhingra H., Raber M.N., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 1993, 85:384-388.
23. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82:1107-1112.
24. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
25. Yoon Y.K., Kim H.P., Han S.W., Oh do Y., Im S.A., Bang Y.J., Kim T.Y. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol. Carcinog. 2010, 49:353-362.
26. Garofalo A., Naumova E., Manenti L., Ghilardi C., Ghisleni G., Caniatti M., Colombo T., Cherrington J.M., Scanziani E., Nicoletti M.I., Giavazzi R. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin. Cancer Res. 2003, 9:3476-3485.
27. Schindlbeck C., Hantschmann P., Zerzer M., Jahns B., Rjosk D., Janni W., Rack B., Sommer H., Friese K. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int. J. Gynecol. Cancer 2007, 17:1047-1055.
28. Deng X., Ruvolo P., Carr B., May W.S. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc. Natl. Acad. Sci. USA 2000, 97:1578-1583.
29. Wikman H., Nymark P., Vayrynen A., Jarmalaite S., Kallioniemi A., Salmenkivi K., Vainio-Siukola K., Husgafvel-Pursiainen K., Knuutila S., Wolf M., Anttila S. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosom. Cancer 2005, 42:193-199.
30. Dhomen N., Marais R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 2007, 17:31-39.
31. Yamamoto T., Ebisuya M., Ashida F., Okamoto K., Yonehara S., Nishida E. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr. Biol. 2006, 16:1171-1182.
32. Cheng M., Sexl V., Sherr C.J., Roussel M.F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc. Natl. Acad. Sci. USA 1998, 95:1091-1096.
33. Arion D., Meijer L., Brizuela L., Beach D. Cdc2 is a component of the M phase-specific histone H1 kinase: evidence for identity with MPF. Cell 1988, 55:371-378.
34. Lees J.A., Buchkovich K.J., Marshak D.R., Anderson C.W., Harlow E. The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J. 1991, 10:4279-4290.
35. Morgan D.O. Principles of CDK regulation. Nature 1995, 374:131-134.
36. Bitangcol J.C., Chau A.S., Stadnick E., Lohka M.J., Dicken B., Shibuya E.K. Activation of the p42 mitogen-activated protein kinase pathway inhibits Cdc2 activation and entry into M-phase in cycling Xenopus egg extracts. Mol. Biol. Cell 1998, 9:451-467.
37. Lin A., Minden A., Martinetto H., Claret F.X., Lange-Carter C., Mercurio F., Johnson G.L., Karin M. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 1995, 268:286-290.
38. Ling Y.H., Consoli U., Tornos C., Andreeff M., Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int. J. Cancer 1998, 75:925-932.
39. Bessard A., Fremin C., Ezan F., Fautrel A., Gailhouste L., Baffet G. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008, 27:5315-5325.
40. Wei F., Xie Y., Tao L., Tang D. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell. Signal. 2010, 22:1783-1789.
41. DeCaprio J.A., Furukawa Y., Ajchenbaum F., Griffin J.D., Livingston D.M. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl. Acad. Sci. USA 1992, 89:1795-1798.
42. Ganansia-Leymarie V., Bischoff P., Bergerat J.P., Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr. Med. Chem. Anticancer Agents 2003, 3:291-306.
43. Clarke P.R., Allan L.A. Cell-cycle control in the face of damage-a matter of life or death. Trends Cell Biol. 2009, 19:89-98.
44. Fujise K., Zhang D., Liu J., Yeh E.T. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J. Biol. Chem. 2000, 275:39458-39465.
45. Craig R.W. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444-454.
46. Skoda C., Erovic B.M., Wachek V., Vormittag L., Wrba F., Martinek H., Heiduschka G., Kloimstein P., Selzer E., Thurnher D. Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck. Oncol. Rep. 2008, 19:1499-1503.
47. Ding Q., Huo L., Yang J.Y., Xia W., Wei Y., Liao Y., Chang C.J., Yang Y., Lai C.C., Lee D.F., Yen C.J., Chen Y.J., Hsu J.M., Kuo H.P., Lin C.Y., Tsai F.J., Li L.Y., Tsai C.H., Hung M.C. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008, 68:6109-6117.
48. Song L., Coppola D., Livingston S., Cress D., Haura E.B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 2005, 4:267-276.
49. Wang J., Lou P., Lesniewski R., Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14:13-19.